BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Net sales of key products [Text Block]

		Three Months Ended March 31,
Dollars in Millions		2013		2012
Virology
Baraclude (entecavir)		$	366	$	325
Reyataz (atazanavir sulfate)			361		358
Sustiva (efavirenz) Franchise			387		386
Oncology
Erbitux* (cetuximab)			162		179
Sprycel (dasatinib)			287		231
Yervoy (ipilimumab)			229		154
Neuroscience
Abilify* (aripiprazole)			522		621
Metabolics
Bydureon* (exenatide extended-release for injectable suspension)			52		N/A
Byetta* (exenatide)			85		N/A
Forxiga (dapagliflozin)			3		N/A
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			202		161
Immunoscience
Nulojix (belatacept)			5		1
Orencia (abatacept)			320		254
Cardiovascular
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			46		207
Eliquis (apixaban)			22		-
Plavix* (clopidogrel bisulfate)			91		1,693
Mature Products and All Other			691		681
	Net Sales	$	3,831	$	5,251